Intensive BP Control Benefits Individuals with Prediabetes, Normoglycemia
Intensive systolic blood pressure (SBP) treatment had similar beneficial effects to standard SBP among participants with prediabetes and normoglycemia, according to a recent study.
The post hoc analysis included 9361 participants enrolled in SPRINT, of whom 3898 participants had prediabetes and 5425 were classified as normoglycic. Composite myocardial infarction and acute coronary syndrome were assessed as the primary outcome. In addition, the effects of intensive SBP treatment on study outcomes were compared with standard SBP treatment among participants with prediabetes and those with normoglycemia.
______________________________________________________________________________________________________________________________________
RELATED CONTENT
Study Examines Effects of Intensive Blood Pressure Lowering on Physical Function
Intensive Blood Pressure Control Reduces Cardiovascular Risks In Older Adults
______________________________________________________________________________________________________________________________________
Over a median 3.26 years of follow-up, the hazard ratio for composite myocardial infarction and acute coronary syndrome was 0.69 for participants with prediabetes and 0.83 for participants with normoglycemia. Hazard ratios for all-cause mortality were 0.77 and 0.71 for participants with prediabetes and normoglycemia who underwent intensive SBP treatment, respectively.
In addition, the effects of intensive SBP treatment compared with standard SBP treatment on prespecific renal outcomes and serious adverse events were similar for those with prediabetes and those with normoglycemia.
“In SPRINT, the beneficial effects of intensive SBP treatment were similar among those with prediabetes and fasting normoglycemia,” the researchers concluded.
—Melissa Weiss
Reference:
Bress AP, King JB, Kreider KE, et al. Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial [published online August 9, 2017]. Diabetes Cares. https://doi.org/10.2337/dc17-0885.